Inhibition of CDKs as a therapeutic modality

Annals of the New York Academy of Sciences

Volumn 910, Issue , 2000, Pages 207-222

  Sausville, Edward A ^a   Johnson, Jill ^a   Alley, Michael ^a   Zaharevitz, Daniel ^a   Senderowicz, Adrian M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N DIMETHYLADENINE; 7 HYDROXYSTAUROSPORINE; 9 NITROPAULLONE; ALSTERPAULLONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; LACTONE DERIVATIVE; NSC 705701; OLOMOUCINE; PAULLONE DERIVATIVE; PURINE DERIVATIVE; PURVALANOL; ROSCOVITINE; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CELL CYCLE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LUNG TOXICITY; LYMPHOCYTOPENIA; MYALGIA; NAUSEA; VOMITING;

EID: 0033913696     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06710.x     Document Type: Conference Paper

References (63)

1. 1. PINES, J. 1995. Cyclins and cyclin dependent kinase: a biochemical view. Biochem. J. 308: 697-711.
2. 2. MORGAN, D.O. 1997. Cyclin dependent kinases: engines, clocks and microprocessors. Ann. Rev. Cell Dev. Biol. 13: 261-291.
3. 3. SHERR, C.J. 1996. Cancer cell cycles. Science 274: 1672-1677.
4. 4. MARLA, A.O., G. DRAETTA, D. BEACH et al. 1989. Reversible tyrosine phosphorylation of cdc2: dephosphorylation accompanies activation during entry into mitosis. Cell 58: 193-203.
5. 5. KREK, W. & E.A. NIGG. 1991. Differential phosphorylation of vertebrate p34cdc2 kinase of the G2/S and G2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J. 10: 305-316.
6. 6. EL-DËIRY, W.S., T. TOKINO, V. VELCULESCU et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
7. 7. HARPER, J.W., G.R. ADAMI, N. WEI et al. 1993. The p21 CDK-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
8. 8. TOYOSHIMA, H. & T. HUNTER. 1994. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78: 67-74.
9. 9. HARPER, J. & S. ELLEDGE. 1996. CDK inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6: 56-65.
10. 10. WEI, P., M. GARBER & S.M. FANG. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV tat and mediates its high-affinity loop-specific binding to TAR RNA. Cell 92: 451-462.
11. 11. HALL, M. & G. PETERS. 1996. Genetic alterations of cyclins, cyclin dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 68: 67-108.
12. 12. LODA, M., B. CUKOR, S.W. TAM et al. 1997. Increased proteosome-dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3: 231-234.
13. 13. PAULOVICH, A.G., D.P. TOCZYNSKI & L.H. HARWELL. 1997. When checkpoints fail. Cell 88: 315-321.
14. 14. EL-DËIRY, W.S., J.W. HARPER, P.M. O'CONNOR et al. 1994. CIP1 is induced in p53-mediated G1 arrest apoptosis. Cancer Res. 54: 1169-1174.
15. 15. POON, R.Y.C., M.S. CHAW, K. YAMASHITA et al. 1997. The role of the cdc2 feedback control loop control in the DNA damage checkpoint in mammalian cells. Cancer Res. 57: 5168-5178.
16. 16. O'CONNOR, P.M. 1997. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 29: 151-182.
17. 17. MEIJER, L. 1995. Chemical inhibitors of cyclin-dependent kinases. In Progress in Cell Cycle Research, Vol. 1. L. Meijer, S. Guidet & H.Y. LimTung, Eds.: 351-363. Plenum Press. New York.
18. 18. BERNHARD, E.J., A. MAITY, R.J. MUSCHEL et al. 1994. Increased expression of cyclin B1 mRNA coincides with diminished G2 arrest in irradiated HeLa cells treated with staurosporine or caffeine. Radiation Res. 140: 393-400.
19. 19. FAN, S., M.L. SMITH, D.J. RIVET II et al. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55: 1649-1654.
20. 20. ALLEY, M.C., C.M. PACULA-COX, M. HURSEY et al. 1991. Morphometric and colorimelric analyses of human tumor cell line growth and drug sensitivity in soft agar culture. Cancer Res. 51: 1247-1252.
21. 21. ALLEY, M.C., C.M. PACULA-COX, M.G. HOLLINGSHEAD et al. 1995. Utility of a PVDF filter plate assay to facilitate selection of tumor cell liver for in vivo drug testing. Proc. Am. Assoc. Cancer Res. 36: 305.
22. 22. SEDLACEK, H.H., J. CZECH, R. NAIK et al. 1996. Flavopiridol (L86-8297, NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9: 1143-1168.
23. 23. KAUR, G., M. STETLER-STEVENSON, S. SEBERS et al. 1992. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. 84: 1736-1740.
24. 24. LOSIEWICZ, M.D., B.A. CARLSON, G. KAUR et al. 1994. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun. 201: 589-595.
25. 25. DEAZEVEDO, W.F., H.J. MUELLER-DIECKMANN, U. SCHULZE-GAHMEN et al. 1996. Structural basis for specificity and potency of a flavonoid kinase. Proc. Natl. Acad. Sci. USA 93: 2735-2740.
26. 26. CARLSON, B.A., M.M. DUBAY, E.A. SAUSVILLE et al. 1996. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and (CDK)4 in human breast carcinoma cells. Cancer Res. 56: 2973-2978.
27. 27. WORLAND, P.H., G. KAUER, M. STETLER-STEVENSON et al. 1993. Alteration of the phosphorylation state of p34 cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem. Pharmacol. 46: 1831-1840.
28. 28. CARLSON, B., T. LAHUSEN, S. SINGH et al. 1999. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59: 4634-4641.
29. 29. PARKER, B.G., G. KAUR, W. NIEVES-NEIRA et al. 1998. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91: 458-465.
30. 30. KONIG, A., G.K. SCHWARTZ, R.M. MOHAMMAD et al. 1997. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates bc12 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90: 4307-4312.
31. 31. BYRD, J.C., C. SHINN, J.K. WASELENKO et al. 1998. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase 3 without evidence of bcl2 modulation or dependence on functional p53. Blood 92: 3804-3816.
32. 32. BIBLE, K.C. & S.M. KAUFMANN. 1996. Flavopiridol: a cytotoxic flavone that induces cell death in non-cycling A549 lung carcinoma cells. Cancer Res. 56: 4856-4861.
33. 33. DREES, M., W.A. DENGLER, T. ROTH et al. 1997. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res. 3: 273-279.
34. 34. PATEL, V., A.M. SENDEROWICZ, P. DECIO et al. 1998. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. 102: 1674-1681.
35. 35. ARGUELLO, F., M. ALEXANDER, J. STERRY et al. 1998. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91: 2482-2490.
36. 36. MELILLO, G., E.A. SAUSVILLE, K. CLOUD et al. 1999. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor (VEGF) expression in human monocytes. Cancer Res. 1: 5433-5437.
37. 37. SENDEROWICZ, A.M., D. HEADLEE, S.F. STINSON et al. 1998. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor in patients with refractory neoplasms. J. Clin. Oncol. 16: 2986-2999.
38. 38. JAGER, W., B. ZEMBSCH, P. WAFSCHANN et al. 1998. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin-dependent kinases, in rat liver. Life Sci. 62: 1861-1873.
39. 39. THOMAS, J., J. CLEARY, K. TUTSCH et al. 1997. Phase I clinical and pharmacokinetic trial of flavopiridol. Proc. Am. Assoc. Cancer Res. 38: 222.
40. 40. GADBOIS, D.M., H.A. CRISSMAN, R.A. TOBEY et al. 1992. Multiple kinase arrest points in the G1 phase of non-transmitted mammalian cells are absent in transformed cells. Proc. Natl. Acad. Sci. USA: 8620-8630.
41. 41. WANG, Q., P.J. WORLAND, J.L. CLARK et al. 1995. Apoptosis in 7-hydroxy staurosporine-treated T lymphoblasts correlates with activation of cyclin dependent kinases 1 and 2. Cell Growth Differ. 6: 927-936.
42. 42. AKIUYAMA T., T. YOSHIDA, T. TSUJITA et al. 1997. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/sdi1 in p53 mutated human epidermoid carcinoma A431 cells. Cancer Res. 57: 1495-1501.
43. 43. SEYNAEVE, C., M. STETLER-STEVENSON, S. SEBERS et al. 1993. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res. 53: 2087-2091.
44. 44. WANG, O., S. FAN, A. EASTMAN et al. 1996. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88: 956-965.
45. 45. BUNCH, R.T. & A. EASTMAN. 1996. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxy staurosporine (UCN-01) a new G2 checkpoint inhibitor. Clin. Cancer Res. 2: 791-797.
46. 46. YU, L., L. ORLANDI, P. WANG et al. 1998. UCN-01 abrogates G2 arrest through a cdc2-dependent pathway that is associated with in activation of the Wee1Hu kinase and activation of the cdc25c phosphatase. J. Biol. Chem. 273: 33455-33464.
47. 47. YU, L., P. GRAVES, Z. TEMPCYZK et al. 1999. The checkpoint kinase Chk1 is a target for the anticancer drug, UCN-01. Proc. Am. Assoc. Cancer Res. 40: 304.
48. 48. SAUSVILLE, E.A., R.D. LUSH, D. HEADLEE et al. 1998. Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models. Cancer Chemother. Pharmacol. 42(Suppl.): S54-S59.
49. 49. FUSE, E., H. TANII, N. KURATA et al. 1998. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein. Cancer Res. 58: 3248-3253.
50. 50. SENDEROWICZ, A.M., D. HEADLEE, R. LUSH et al. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Presented at the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.
51. 51. VESELY, J., L. HAVLICEK, M. STRAD et al. 1994. Inhibition of cyclin-dependent kinases by purine analogs. Eur. J. Biochem. 224: 771-786.
52. 52. MEIJER, L., A. BORGNE, O. MULNER et al. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin dependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 243: 527-536.
53. 53. SCHULZE-GAHMEN, U., J. BRANDSEN, H.D. JONES et al. 1995. Multiple modes of ligand recognition: crystal structures of cyclin dependent kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins Struct. Funct. Genet. 22: 378-391.
54. 54. BROOKS, E.E., N.S. GRAY, A. JOLY et al. 1997. CVT 313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J. Biol. Chem. 272: 29207-29211.
55. 55. GRAY, N.S., L. WODICKA, A.M. THUNNISEN et al. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533-538.
56. 56. BUQUET-FAGOT, C., F. LALLEMARD, M.N. MONTAGNE et al. 1997. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell liver. Anti-Cancer Drug 8: 623-638.
57. 57. ARRIS, C.E., F.T. BOYLE, A.M. CALVERT et al. 1999. Comparative inhibition of CDK1 and CDK2 by 6-substituted purines and 4-substituted pyrimidines. Proc. Am. Assoc. Cancer Res. 40: 305.
58. 58. ZAHAREVITZ, D.W., R. GUSSIO, M. LEOST et al. 1999. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59: 2566-2569.
59. 59. SCHULTZ, C., A. LINK, M. LEOST et al. 1999. The paullones, a series of cyclin-dependent kinase inhibitors synthesis. Evaluation of CDK1/cyclin B inhibition and in vitro antitumor activity. J. Med. Chem. 42: 2909-2919.
60. 60. FAHREUS, R., S. LAIN, K.L. BALL et al. 1998. Characterization of the cyclin dependent kinase inhibition domain of the INK4 family as a model for a synthetic tumor suppressor molecule. Oncogene 16: 587-596.
61. 61. BONFANTI, M., S. TAVERNA, M. SALMONA et al. 1997. p21 WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res. 57: 1442-1446.
62. WAF1. Curr. Biol. 7: 71-80.
63. 63. MOBLEY, S.R., T.J. LIU, J.M. HUDSON et al. 1998. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy. Arch. Otolaryngol. Head Neck Surg. 124: 88-92.